The Centers for Medicare & Medicaid Services Nov. 26 proposed changes to increase oversight of the Medicare Advantage and prescription drug programs for contract year 2026.
Officials want people to understand just how narrow their window to sign up for flexible gap-filler coverage is.
Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...
Related: Crazy-expensive weight loss drugs may soon see a major change In other news, The Biden Administration is set to ...
If all of Trump’s choices are confirmed, the Cabinet is set to be less diverse than the preceding Biden administration.
The proposal would let patients get Wegovy, Ozempic and related drugs for obesity, which Medicare and Medicaid does not cover ...
Medicare Advantage plans' prior authorization rules and coverage criteria would become publicly available under a proposed ...
The Centers for Medicare & Medicaid Services (CMS) is proposing new limits on Medicare Advantage (MA) plans regarding prior authorization, utilization ...
The proposed rule could give millions of Americans access to the new drugs; it will also put pressure on the incoming Trump administration.
More than seven million additional Americans could get coverage for popular drugs such as Zepbound and Wegovy under the ...
CMS proposes changes to Medicare and Medicaid to cover weight-loss drugs, recognizing obesity as a disease. This could expand ...
The state discovered a glitch in its Medicaid eligibility system. The problem, alleged in court testimony, led to new mothers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback